Literature DB >> 27890249

Early outcomes of Pyrocardan® implants for trapeziometacarpal osteoarthritis.

T M A S Lauwers1, K Brouwers2, H Staal3, L T Hoekstra2, R R W J van der Hulst2.   

Abstract

The aim of this retrospective study was to assess the early outcomes of trapeziometacarpal osteoarthritis treatment using Pyrocardan® implants in patients with early Eaton (stage I and II) osteoarthritis. We analyzed the results of 27 patients, with a median age of 59 years (range, 34-78 years) and a mean follow-up of 24 months (range, 12-41). The level of satisfaction was assessed using a postoperative questionnaire. Twenty patients mentioned having improvements in their activities of daily living, 20 patients were satisfied with the outcomes of surgery, and 19 patients would consider undergoing the procedure a second time. Five patients needed reoperation for complications, including persistent pain, grinding, or implant dislocation. Pyrocardan® implants may be a valuable temporary therapy as more conventional arthroplasty techniques are still feasible in case of failure. However, multicenter randomized controlled trials with a longer follow-up are needed to assess the long-term outcomes. Copyright Â
© 2016 SFCM. Published by Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Arthroplastie; Arthroplasty; Implant Pyrocardan(®); Pyrocarbon; Pyrocarbone; Pyrocardan(®) implant; Rhizarthrose; Trapeziometacarpal osteoarthritis

Mesh:

Year:  2016        PMID: 27890249     DOI: 10.1016/j.hansur.2016.09.004

Source DB:  PubMed          Journal:  Hand Surg Rehabil        ISSN: 2468-1210            Impact factor:   0.969


  2 in total

1.  Pyrocardan Trapeziometacarpal Joint Arthroplasty-Medium-Term Outcomes.

Authors:  James Logan; Susan E Peters; Ruby Strauss; Silvia Manzanero; Gregory B Couzens; Mark Ross
Journal:  J Wrist Surg       Date:  2020-08-21

2.  Pyrocardan® interpositional arthroplasty for trapeziometacarpal osteoarthritis: a minimum four year follow-up.

Authors:  Francesco Smeraglia; Morena Anna Basso; Giulia Famiglietti; Andrea Cozzolino; Giovanni Balato; Alessio Bernasconi
Journal:  Int Orthop       Date:  2022-06-08       Impact factor: 3.479

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.